Wockhardt Recalls Amlodipine Besylate Tablets Due to CGMP Deviations
Wockhardt USA is recalling Amlodipine Besylate 5 mg tablets because the firm did not adequately investigate customer complaints.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically indicates a reasonable probability of temporary or medically reversible health consequences. The specific deviation is a documentation/investigation failure (CGMP) rather than a direct physical hazard like contamination or mislabeling, fitting the Moderate severity criteria for minor labeling or documentation issues.
Plain-English summary
Wockhardt USA LLC is recalling Amlodipine Besylate Tablets, 5 mg, in 90-count and 1,000-count bottles. The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations, specifically because the firm did not adequately investigate customer complaints.
The affected product is distributed nationwide in the United States, including Puerto Rico. The recall includes specific lot numbers with expiration dates ranging from April 2015 to March 2016. The total quantity involved is 146,959 bottles of the 90-count packaging and 73,445 bottles of the 1,000-count packaging.
Consumers with these specific lot numbers should stop using the medication and contact their healthcare provider or pharmacist for guidance on replacement or disposal.
The recalled product
- Product
- Amlodipine Besylate Tablets, 5 mg Tablets, Packaged as A) 90 Count Bottles (NDC: 64679-422-01) and B) 1000 Count Bottles (NDC: 64679-422-02), Rx Only. Manufactured by: Wockhardt Limited, Mumbai, India. Distributed by: Wockhardt USA LLC 20 Waterview Blvd. Parsippany, NJ 07054 USA
- Manufacturer
- Wockhardt Usa Inc.
- Category
- Drug — Antihypertensive
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- A) Lot #: DM11421
- Expiry: 5/31/2015
- Lot #: DM12956
- Expiry: 10/31/2015
- Lot #: DM12957
- Lot #: DM12963
- Lot #: DM13242
- Expiry: 11/30/2015
- Lot #: DM13243
- Lot #: DM13251
- Lot #: DM13260
- Lot #: DN10138
- Expiry: 12/31/2015. B) Lot #: DM11035
- Expiry: 4/30/2015
- Lot #: DM11088
- Lot #: DM11389
- Lot #: DM11393
- Lot #: DM11394
- Lot #: DM12632
- Expiry: 9/30/2015
Distribution
Part of a larger recall action
This product is one of 35 recalled by Wockhardt Usa Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 35 products in this recall →Related recalls
Same manufacturer · Wockhardt Usa Inc.
See all →- LowWockhardt Recalls Enalapril Maleate Tablets Due to Impurity Failures
FDA (Drugs) · 2017-11-01
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Lisinopril Tablets Due to Inadequate Complaint Investigations
FDA (Drugs) · 2015-08-26
- ModerateWockhardt Recalls Azithromycin Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
- ModerateWockhardt Recalls Zolpidem Tartrate Tablets Due to Complaint Investigation Failures
FDA (Drugs) · 2015-07-29
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19